Ultrasonic response persulfate-based interventional embolization agent and preparation and application thereof

Through ultrasonic-responsive persulfate-based interventional embolizer, ultrasonic stimulation releases reactive oxygen and calcium ions, the problem of insufficient tumor vascular blockade and nanodrug enrichment in hepatocellular carcinoma treatment was solved, and efficient liver cancer treatment effect was achieved.

CN118903526APending Publication Date: 2024-11-08SHANGHAI UNIV OF ENG SCI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410854492.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing hepatocellular carcinoma treatment methods such as transcatheter arterial embolization (TAE) are difficult to completely block tumor blood vessels, and nanomedicines are insufficiently enriched in the tumor site, resulting in limited treatment effects and safety issues.

Method used

Develop an ultrasonic-responsive persulfate-based interventional embolizer, synthesize calcium-doped persulfate nanomaterials by magnetic stirring at room temperature, and modify it with lecithin and DSPE-PEG2000, combine with iodine oil to form LDCNSO-IEA interventional embolization The agent can quickly release reactive oxygen free radicals and calcium ions under ultrasound stimulation, damage tumor cells.

Benefits of technology

It has achieved efficient tumor cell damage and apoptosis in the treatment of liver cancer, overcomes the insufficient enrichment and safety of traditional nano drugs in the tumor site, and provides new ideas for interventional treatment of liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903526A_ABST
    Figure CN118903526A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of intelligent medicaments, and relates to an ultrasonic response persulfate-based interventional embolism agent and preparation and application thereof.The preparation method comprises the steps that firstly, calcium oleate, oleic acid and ammonium persulfate are subjected to a coordination reaction, and CNSO is obtained; then, lecithin, DSPE-PEG and CNSO are subjected to a reaction in an organic solvent, and LDCNSO is obtained; and finally, mixing the iodinated oil with LDCNSO to obtain the persulfate-based interventional embolization agent. Compared with the prior art, the prepared ultrasonic response persulfate-based interventional embolization agent solves the problem that a traditional nano-drug is less enriched at a tumor site and the safety problem to a certain extent. Meanwhile, the problems that a single treatment mode is poor in treatment effect, easy to relapse and the like are solved through synergistic treatment, and the medicine has a wide clinical application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of intelligent medicines, and relates to an ultrasonically responsive persulfate-based interventional embolic agent and a preparation and application thereof. Background Art

[0002] Liver cancer is the most common cause of cancer death worldwide and is the only one of the top five deadliest cancers with a continuously increasing percentage of new cases each year. Predisposing factors for liver cancer include hepatitis B virus, hepatitis C virus, obesity and fatty liver, diabetes, cirrhosis caused by drinking, smoking, iron overload and various unhealthy diets. The prognosis of liver cancer is poor. Only early-stage patients are eligible for surgical resection, accounting for only 5% to 15%; compared with left hepatectomy, right hepatectomy has a higher risk of complications.

[0003] Transcatheter arterial embolization (TAE) is currently recognized as the most popular treatment for hepatocellular carcinoma (HCC). In TAE, an interventional embolic agent (IEA) is injected into the tumor-feeding artery to block the flow of oxygen and essential nutrients to the HCC, ultimately inducing tumor necrosis. Unfortunately, due to the abundant tumor capillaries in the tumor, it is difficult for TAE to completely block the entire blood vessel. In addition, TAE has limitations in effectively inhibiting tumor growth, mainly due to the high metastasis and regeneration rates of HCC, which can repair itself. The passive targeting effect (EPR effect) and active targeting function of nanomedicines can cause the drug to accumulate at the tumor site, but the enrichment is still relatively small, and in many cases, it cannot reach an effective drug concentration. In addition, during the drug circulation process, the reticuloendothelial system will take up the nanomedicine and clear it, causing systemic toxic side effects and reduced enrichment at the tumor site. In order to meet the above challenges, it is imperative to explore strategies that can improve the therapeutic effect of transarterial embolization (TAE) and overcome the barriers to nanodrug delivery. One idea is to combine nanodrugs that produce reactive oxygen species (ROS) with TAE treatment to prepare new embolic agents for the treatment of HCC. Summary of the invention

[0004] The purpose of the present invention is to provide an ultrasound-responsive persulfate-based interventional embolic agent and its preparation and application, which are used to solve the limited therapeutic effect of transarterial chemoembolic agents and the safety problems of traditional nanomedicines, and avoid the metastasis and recurrence of liver cancer.

[0005] Transarterial chemoembolization is one of the most popular liver-targeted treatments for liver tumors, especially hepatocellular carcinoma. The purpose of TACE is to embolize the tumor and deliver chemotherapy drugs through a catheter-based intra-arterial route. Different embolization strategies have been developed over the years. However, the basic approach is to use chemotherapy drugs mixed with drug-loaded embolic materials, and deliver the drug-loaded embolic agents into the target part under the guidance of digital subtraction angiography (DSA) to form emboli and release drugs in situ to achieve the therapeutic purpose.

[0006] Sonodynamic therapy (SDT) can kill malignant tumors by using sonosensitizers and low-intensity ultrasound (US) at the same time. As a new cancer treatment, it has gradually come into people's view. As a new non-invasive therapy developed based on photodynamic therapy (PDT), sonodynamic therapy (SDT) has attracted widespread attention in the field of cancer treatment in the past few decades. Similar to PDT, low frequency (<3MHz) and low intensity (<3W / cm 2 ) is used to excite ultrasound sensitizers and induce reactive oxygen species (ROS) production to damage tumor cells via SDT, which has a deeper soft tissue penetration depth than laser and has better clinical application and translational potential.

[0007] As a class of highly oxidizing chemicals, ROS can cause oxidative damage to tumor cells, leading to apoptosis and necrosis of tumor cells and exerting anti-tumor effects. Therefore, the great potential of ROS-based cancer treatment strategies has been tapped. However, due to the limitations of weak acid, hypoxia, and insufficient endogenous hydrogen peroxide content in tumors, the ROS-mediated therapeutic effect is not obvious; and as a representative of ROS, ·OH has a short half-life and insufficient diffusion distance in cells, which seriously limits its therapeutic effect.

[0008] In recent years, sulfate radical (·SO4 - ) has been gradually explored. It has the characteristics of a longer half-life than ·OH, a higher standard redox potential than other reactive oxygen species, and is independent of oxygen and pH, making it particularly suitable for tumor hypoxia and acidic microenvironment. - Peroxymonosulfate (PMS) and peroxydisulfate (PDS) have shown great promise in reactive oxygen species-mediated cancer therapy.

[0009] Intracellular ions play a key role in cell metabolism and proliferation. More and more studies have found that ion homeostasis imbalance may induce cell dysfunction and even cell death. Calcium overload can activate the mitochondrial apoptosis pathway of cell damage. Therefore, in this sense, ion interference strategy as an effective means of cancer treatment can be fully recognized.

[0010] The present invention aims to develop an advanced, safe and efficient interventional embolic agent for interventional embolic treatment of liver cancer by combining the deep tissue penetration ability of ultrasound, cell oxidative stress caused by ROS and ion interference strategy. The present invention first synthesizes a new calcium-doped persulfate nanomaterial CNSO by a room temperature magnetic stirring method, and successfully modifies it with lecithin and DSPE-PEG2000 to improve its stability in a physiological environment. Finally, LDCNSO nanoparticles are uniformly mixed with iodized oil to obtain LDCNSO-IEA interventional embolic agent. LDCNSO-IEA disintegrates rapidly under ultrasonic stimulation, on the one hand, quickly releasing SO4 - , ·OH and ·O2 - The reactive oxygen free radicals that are toxic to tumor cells cause oxidative stress damage to tumor cells. On the other hand, the rapid release of Ca 2+ It causes calcium overload in tumor cells, damages the mitochondria of cells, and together causes a large number of tumor cells to undergo apoptosis and necrosis. The present invention combines TAE with LDCNSO drugs that produce ROS by sound catalysis, solves the problems associated with traditional ROS drugs, and can be used as an efficient embolic agent for tumor interventional treatment, bringing broad prospects for the treatment of HCC.

[0011] The purpose of the present invention can be achieved by the following technical solutions:

[0012] A method for preparing a persulfate-based interventional embolic agent comprises the following steps:

[0013] S1: Calcium oleate, oleic acid, and ammonium persulfate are coordinated to obtain Ca-(NH4)2S2O8 NPs (CNSO);

[0014] S2: reacting lecithin, DSPE-PEG and CNSO in an organic solvent to obtain LDCNSO;

[0015] S3: Mix iodized oil with LDCNSO to obtain a persulfate-based interventional embolic agent.

[0016] Furthermore, in step S1, the feed ratio of calcium oleate, oleic acid and ammonium persulfate is 40 mg:1 mL:20 mg.

[0017] Furthermore, in step S1, in the coordination reaction, the reaction solvent is a mixture of n-hexane and ethanol, and the mixing volume ratio is 10:3; the reaction temperature is room temperature, and the reaction time is 12 hours.

[0018] Preferably, the ratio of calcium oleate, oleic acid, n-hexane, ethanol and ammonium persulfate is: 40 mg: 1 mL: 10 mL: 3 mL: 20 mg.

[0019] Furthermore, in step S1, the preparation method of calcium oleate comprises: subjecting sodium hydroxide, oleic acid and calcium chloride to a hydrothermal reaction, and post-processing to obtain calcium oleate.

[0020] Furthermore, the mass ratio of the sodium hydroxide, oleic acid and calcium chloride is 0.18g:1.16g:0.625g.

[0021] Furthermore, in the hydrothermal reaction, the reaction temperature does not exceed 90° C., and is preferably 90° C., and the reaction time is 15 min.

[0022] Furthermore, the post-treatment is as follows: after the reaction, the obtained suspension is washed three times and then filtered, and the filter residue is dried at 105° C. for 2 hours to obtain yellow solid calcium oleate.

[0023] Furthermore, in step S1, the coordination reaction is followed by post-treatment to obtain LDCNSO, wherein the post-treatment is to wash the solution obtained after the reaction by centrifugation, and then dry it at room temperature for later use.

[0024] Further, step S2 includes:

[0025] S2-1: Add lecithin and DSPE-PEG to chloroform to obtain a chloroform phospholipid solution; mix CNSO with n-hexane to obtain a CNSO suspension;

[0026] S2-2: Mix the chloroform phospholipid solution and the CNSO suspension, and stir to react to obtain LDCNSO.

[0027] Furthermore, in step S2-1, the dosage ratio of lecithin, DSPE-PEG, and chloroform is 1 mg:1 mg:1 mL;

[0028] The feed ratio of CNSO to n-hexane is 25 mg:25 mL.

[0029] Furthermore, in step S2-2, in the chloroform phospholipid solution and the CNSO suspension, the feed ratio of CNSO to the chloroform phospholipid solution is 25 mg:5 mL.

[0030] Furthermore, in step S2-2, in the reaction, the reaction temperature is room temperature and the reaction time is 12 hours.

[0031] Furthermore, in step S2-2, after the reaction, post-treatment is also included, and the post-treatment is to remove the solvent by rotary evaporation to form a film, and then resuspend and centrifuge to wash and dry.

[0032] Furthermore, during the rotary evaporation process, the vacuum degree was 0.1 MPa, the rotation speed was 20 rpm, and the evaporation temperature was 45°C;

[0033] Furthermore, during the washing process, the centrifuge speed was 8000 rpm and the drying temperature was room temperature.

[0034] Furthermore, in step S3, the content of LDCNSO in the persulfate-based interventional embolic agent is 60 mg / kg.

[0035] The second aspect of the present invention provides a use of a persulfate-based interventional embolic agent, including using the persulfate-based interventional embolic agent to prepare an anti-tumor drug, especially for combined treatment of ultrasound and interventional surgery.

[0036] The second aspect of the present invention provides an application of a persulfate-based interventional embolic agent, including application of the persulfate-based interventional embolic agent in the preparation of a drug loaded with persulfate or persulfate nanoparticles.

[0037] The ultrasound-responsive persulfate-based interventional embolic agent prepared by the present invention solves the problem of low accumulation of traditional nanomedicines in tumor sites and safety issues to a certain extent. At the same time, synergistic treatment also alleviates the problems of poor treatment effect and easy recurrence of single treatment methods, and has broad clinical application prospects.

[0038] Compared with the prior art, the present invention has the following characteristics:

[0039] (1) The preparation method of the present invention mixes the pre-synthesized LDCNSO nanoparticles with iodized oil and prepares them on the spot to prepare LDCNSO-IEA embolic agent which has good stability under physiological conditions and ensures efficient treatment effect under the guidance of DSA.

[0040] (2) The preparation method of the present invention can obtain an excellent reactive oxygen generator with extremely strong ultrasound sensitivity. Under the catalysis of ultrasound, a large amount of reactive oxygen is generated to directly kill tumor cells. In addition, after LDCNSO enters the cell through endocytosis, the released Ca 2+ It will cause intracellular calcium overload, further leading to mitochondrial damage and cell apoptosis. LDCNSO also has the ability to consume GSH, thereby weakening the antioxidant capacity of tumors and further improving the therapeutic effect.

[0041] (3) The novel embolic agent prepared by the present invention provides a new idea for the treatment of liver cancer, overcoming the problem of low accumulation of traditional nanomedicines in the lesion site. Local administration can solve the safety problem of nanomedicines to a certain extent, and is expected to achieve in situ treatment of liver cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 This is the TEM image of CNSO in Example 2.

[0043] Figure 2This is a graph showing the change in hydrated particle size of LDCNSO in Example 3 within 7 days.

[0044] Figure 3 This is a graph showing the change in hydrated particle size of LDCNSO-IEA in Example 4 within 7 days.

[0045] Figure 4 This is the element mapping diagram of CNSO in Example 2.

[0046] Figure 5 The powder X-ray diffraction patterns and crystal structure diagrams of CNSO and LDCNSO nanoparticles in Examples 2 and 3.

[0047] Figure 6 This is the full X-ray photoelectron spectrum of CNSO in Example 2, as well as the fine spectrum of each element.

[0048] Figure 7 This is the Fourier transform infrared spectrum of LDCNSO in Example 3.

[0049] Figure 8 This is the UV spectrum of the MB degradation experiment of LDCNSO in Example 3.

[0050] Fig. 9 The diagram shows the cytotoxicity of LDCNSO to L929 and VX2 cells in Example 3, and the therapeutic effect of ultrasound on VX2 cells.

[0051] Fig.10 This is the calcium ion release diagram of LDCNSO at different pH under different treatment conditions in Example 3.

[0052] Fig.11 The LDCNSO in Example 3 was used to detect intracellular Ca in different treatment groups using Fluo-4 AM fluorescent probe. 2+ Fluorescence image of the content.

[0053] Fig.12 This is a biological electron microscopy image of VX2 cells after LDCNSO treatment in Example 3.

[0054] Fig.13 In order to successfully establish an orthotopic liver cancer model in New Zealand white rabbits, the animals in each group (normal saline treatment, iodized oil + US group, LDCNSO-IEA group, LDCNSO-IEA + US group) were treated with different treatment methods / drugs. 18 F FDG-PET / CT imaging test and pathological section results after treatment. DETAILED DESCRIPTION

[0055] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0056] A method for preparing an ultrasound-responsive persulfate-based interventional embolic agent comprises the following steps:

[0057] (1) NaOH (sodium hydroxide), oleic acid and CaCl2 (anhydrous calcium chloride) undergo hydrothermal reaction, and post-treatment to obtain pale yellow solid calcium oleate;

[0058] (2) dissolving the calcium oleate and oleic acid prepared in step (1) in an organic solvent, adding ammonium persulfate to cause a coordination reaction, and post-treating to obtain CNSO;

[0059] (3) dissolving lecithin and DSPE-PEG2000 in chloroform to obtain a chloroform phospholipid solution;

[0060] (4) firstly re-spin the CNSO prepared in step (2) with n-hexane, then mix the suspension with the chloroform phospholipid solution, stir and post-treat to obtain LDCNSO;

[0061] (5) mixing iodized oil and the LDCNSO prepared in step (4) to obtain an ultrasound-responsive persulfate-based interventional embolic agent.

[0062] In one embodiment of the present invention, NaOH and CaCl2 are dissolved in aqueous solution respectively.

[0063] In one embodiment of the present invention, in step (1), the mass ratio of NaOH, oleic acid and CaCl2 is 0.18g:1.16g:0.625g;

[0064] During the hydrothermal process, the reaction temperature was 90 °C and the reaction time was 15 min;

[0065] In one embodiment of the present invention, during the reaction, NaOH, oleic acid and CaCl2 are added to water in sequence; the entire reaction process is carried out at 90°C.

[0066] In one embodiment of the present invention, in step (1), the post-treatment is to wash the suspension obtained after the reaction three times and then filter it with suction, and the filter residue is dried at 105° C. for 2 h to obtain yellow solid calcium oleate.

[0067] In one embodiment of the present invention, calcium oleate and oleic acid are dissolved in a mixed solution of n-hexane and ethanol, respectively, and ammonium persulfate is added.

[0068] In one embodiment of the present invention, in step (2), the ratio of calcium oleate, oleic acid, n-hexane, ethanol and ammonium persulfate is: 40 mg: 1 mL: 10 mL: 3 mL: 20 mg.

[0069] During the coordination reaction, the reaction temperature was room temperature and the reaction time was 12 h;

[0070] In one embodiment of the present invention, in step (2), the post-treatment is to wash the solution obtained after the reaction by centrifugation, and then dry it at room temperature for later use.

[0071] In one embodiment of the present invention, in step (3), the ratio of lecithin, DSPE-PEG2000 and chloroform is 1 mg:1 mg:1 mL;

[0072] In one embodiment of the present invention, in step (4), the usage ratio of CNSO, n-hexane and chloroform phospholipid solution is 25 mg:25 mL:5 mL.

[0073] In one embodiment of the present invention, in step (4), the post-treatment is to remove the solvent by rotary evaporation to form a thin film, and then resuspend and centrifuge to wash and dry.

[0074] During the rotary evaporation process, the vacuum degree was 0.1 MPa, the rotation speed was 20 rpm, and the evaporation temperature was 45 °C;

[0075] During the washing process, the centrifuge speed was 8000 rpm and the drying temperature was room temperature.

[0076] The present invention provides an ultrasound-responsive persulfate-based interventional embolic agent prepared by the method.

[0077] The present invention provides an application of an ultrasound-responsive persulfate-based interventional embolic agent in the preparation of a drug loaded with persulfate or persulfate nanoparticles.

[0078] This embodiment is implemented based on the technical solution of the present invention, and provides a detailed implementation method and a specific operation process, but the protection scope of the present invention is not limited to the following embodiments.

[0079] Example 1

[0080] This embodiment provides a method for preparing calcium oleate, comprising:

[0081] Add 50 mL of ultrapure water to a 250 mL three-necked flask, connect a condensing reflux device, preheat to 90 ° C in an oil bath, add 0.18 g of NaOH, stir at 200 rpm for 5 min, add 1.16 g of oleic acid, continue stirring for 10 min, add CaCl2 solution (0.625 g of anhydrous calcium chloride dissolved in 5 mL of ultrapure water) dropwise to obtain a white precipitate, filter it out, wash with ultrapure water until there is no chloride ion, drain it, and bake it in an oven at 105 ° C for 45 min to transform it into a light yellow, transparent solid, which is calcium oleate.

[0082] Example 2

[0083] This embodiment provides a method for preparing CNSO, comprising:

[0084] 40 mg of calcium oleate, 1 mL of oleic acid, 10 mL of n-hexane, and 3 mL of anhydrous ethanol were ultrasonically dispersed, transferred to a 20 mL reaction bottle and stirred at 300 rpm for 10 min, 20 mg of ammonium persulfate was added, and the reaction was continued at room temperature with stirring for 12 h. After stopping stirring, the upper turbid liquid was quickly aspirated (without absorbing the insoluble matter at the bottom), and the mixture was centrifuged at 8000 rpm and 8°C for 10 min. The supernatant was discarded, 6 mL of n-hexane and 2 mL of anhydrous ethanol were added for ultrasonic suspension, and the mixture was centrifuged at 8000 rpm and 8°C for 10 min. The mixture was washed 3 times in total, and then volatilized in a fume hood for 2-3 h to obtain CNSO powder.

[0085] Figure 1 This is a TEM image of the CNSO prepared in this example. It can be seen from the image that the size distribution of the prepared CNSO is uniform, and the size is about 150nm.

[0086] Figure 4 This is the element mapping diagram of CNSO prepared in this example. It can be seen from the figure that the prepared nanoparticles contain four elements, Ca, N, S, and O, and the elements are evenly distributed in the nanoparticles, which proves the successful synthesis of CNSO and the successful doping of Ca element.

[0087] Figure 6 The X-ray photoelectron spectrum of CNSO prepared in this example (a) is the full spectrum, and (b) is the fine spectrum of each element. It can be seen from the figure that the high-resolution XPS spectrum further determines the valence state of Ca, N, S and O elements in CNSO. Specifically, in the spectrum of Ca 2p, two main peaks at 347.5eV and 351.0eV were observed, indicating that divalent free calcium ions have been successfully loaded. The spectra of N 1s and S2p verify the synthesis of (NH4)2S2O8. In the high-resolution spectrum of O1s, the two peaks at 531.0eV and 532.8eV come from O 2- and O2 2- , these data together confirm the successful synthesis of CNSO.

[0088] Example 3

[0089] This embodiment provides a method for preparing LDCNSO, comprising:

[0090] Phospholipid surface modification: First prepare a chloroform phospholipid solution (1 mg lecithin, 1 mg DSPE-PEG 2000 dissolved in 1 mL chloroform), disperse 25 mg of the CNSO prepared in Example 2 in 25 mL of n-hexane, and ultrasonically disperse for 30 s. Add 5 mL of the chloroform phospholipid solution dropwise to the CNSO dispersion, and ultrasonically disperse for 30 s. Stir in a 50 mL reaction bottle at room temperature and 500 rpm overnight to obtain a turbid solution.

[0091] Rotary evaporation and washing: The modified turbid liquid is transferred into a clean 500mL rotary evaporation bottle, and the rotary evaporation device is evacuated to 0.1MPa, and condensed water at 4°C is passed, and the rotary evaporation is performed at 20rpm, and the chloroform is heated in a water bath (45°C) while the rotary evaporation is performed. After the chloroform is completely evaporated, the rotary evaporation is continued for 10 minutes. Then the product in the rotary evaporation bottle is scraped out and transferred to a high-speed centrifuge tube, and then the rotary evaporation bottle is washed with 12mL of n-hexane and 4mL of anhydrous ethanol, and the washing liquid is transferred to a high-speed centrifuge tube, ultrasonically treated for 30s, centrifuged at 8000rpm, and 8°C for 10min, the supernatant is discarded, 6mL of n-hexane and 2mL of anhydrous ethanol are added for ultrasonic suspension, and then washed twice, and then placed in a fume hood for 2-3h to obtain a LDCNSO nanoparticle sample.

[0092] Figure 2 The dimensional change of the LDCNSO prepared in this example in water is shown in the figure. As can be seen from the figure, the hydrated particle size of the prepared LDCNSO has no obvious change within 7 days, proving that it has colloidal stability in water.

[0093] Figure 5 (a) Powder X-ray diffraction (XRD) pattern of nanoparticles of CNSO and LDCNSO prepared in this example and (b) schematic diagram of crystal structure. It can be seen from the figure that in the crystal structure of LDCNSO, a part of N is replaced by Ca, thereby proving the successful doping of Ca.

[0094] Figure 7 The Fourier transform infrared spectrum of LDCNSO prepared in this example shows that oleic acid and the material CNSO before phospholipid modification have a wavelength of 1420 cm -1 There are characteristic absorption peaks of NH2 and CN at 1344cm -1 ~963cm -1 S2O8 2- The infrared absorption peak shape of (NH4)2S2O8 proves the successful synthesis of (NH4)2S2O8. In addition, LDCNSO has a peak absorption of 1727 cm -1 The characteristic absorption peak of PO appeared at the 40°C, which was attributed to the successful modification of CNSO by lecithin and phospholipid polyethylene glycol (DSPE-PEG2000), thereby improving the stability of CNSO in water, slowing down its collapse in the tumor microenvironment, and prolonging its retention time in the tumor site.

[0095] Example 4

[0096] This embodiment provides a method for preparing an LDCNSO interventional embolic agent, comprising:

[0097] LDCNSO and iodized oil were mixed and stirred until completely mixed to obtain LDCNSO interventional embolic agent (LDCNSO-IEA), wherein the concentration of LDCNSO was 60 mg / kg.

[0098] Figure 3 The dimensional change of the LDCNSO-IEA prepared in this example in water is shown in the figure. As can be seen from the figure, the hydrated particle size of the prepared LDCNSO-IEA decreases slowly as the iodized oil is metabolized.

[0099] Figure 8 The ability of LDCNSO prepared in this example to decolorize MB (a) in water; (b) in iodized oil. As shown in the figure, the trace ROS produced by 50ppm LDCNSO in aqueous solution hardly decolorizes MB, and after 1min of ultrasonic excitation, the absorbance of MB decreases rapidly. Similarly, the ability of LDCNSO-IEA in iodized oil to release reactive oxygen species under ultrasonic excitation is still good, which indicates that LDCNSO-IEA has application prospects in interventional surgical treatment.

[0100] Example 5

[0101] First, the rabbit VX2 tumor was minced and a tumor suspension (1×10 7 / mL viable cell concentration), and then 0.5mL of the suspension was injected into the leg muscle of adult male New Zealand white rabbits. After 1-2 weeks, the well-grown tumor tissue was removed, and the surrounding muscle tissue was removed. The selected active tumor tissue was cut into pieces and placed in physiological saline for later use.

[0102] After fasting the experimental rabbits for 12 hours, 6-month-old male New Zealand white rabbits were selected for tumor transplantation. During the transplantation process, the rabbits were kept breathing smoothly at all times. After shaving the hair on the xiphoid process of the rabbits, they were disinfected with iodine tincture, and a 3-4 cm incision was made under the sternum. The tissues were removed layer by layer to expose the liver lobes. A 3-4 mm incision was made in the thicker area of ​​the liver lobes with tweezers, and a 2-3 mm tumor mass was implanted. Hemostatic powder was used to stop bleeding, and then the liver was returned to its original position. A small amount of penicillin was injected into the chest cavity and the wound was sutured layer by layer.

[0103] Two weeks after the VX2 tumor was transplanted into the experimental rabbit, FDG-PET / CT imaging was performed to verify whether the tumor had formed. After the experimental rabbits were fasted for 8 hours, they were placed in a prone position under an isoflurane gas anesthesia machine to maintain anesthesia, and the ear vein was injected with 18 F-FDG solution, the dosage per piece is about 7.2-10.8MBq. 1860 minutes after the F-FDG solution was injected into the experimental rabbit, the whole body PET / CT imaging was performed. The tube voltage of CT was set to 120 kV, the tube current was adjusted to 100 mA, and the image acquisition time was 18 1 hour after F-FDG administration. Finally, the target area was selected in the liver tissue on the PET image to obtain the SUV max value.

[0104] The rabbits were randomly divided into different groups, with 3 rabbits in each group: (1) control group; (2) iodized oil + US group; (3) LDCNSO-IEA group; (4) LDCNSO-IEA + US group.

[0105] LDCNSO-IEA+US group: Rabbits were injected with 2wt% sodium pentobarbital at 30mg / kg via ear vein. After anesthesia, the groin was shaved, an incision was made, and the tissue was gently pushed aside to expose the femoral artery. The puncture needle of the interventional kit was used for puncture, and then a microcatheter was introduced through the needle. Under the guidance of DSA, the position of the catheter was adjusted through the guide wire so that its port was at the branch blood vessel supplying the liver tumor. 1mL LDCNSO-IEA was used for embolization. The tissue and incision were sutured at the end of the operation. Ultrasound intervention was performed 3 days after surgery, and the ultrasound parameter was 1W / cm 2 , continue, 10min. 8 days after surgery 18 F FDG-PET / CT imaging to evaluate the biological activity of liver cancer, verify the treatment effect, and obtain SUV max The VX2-bearing rabbits were then euthanized and tumor tissue samples were collected. These samples were fixed in 4% paraformaldehyde for further histopathological (H&E / TUNEL staining) evaluation.

[0106] Compared with the LDCNSO-IEA+US group, the LDCNSO-IEA group did not undergo ultrasound, and the rest was the same.

[0107] In the iodized oil + US group, compared with the LDCNSO-IEA + US group, the amount of iodized oil was the same, LDCNSO was not added, and the rest was the same.

[0108] In the control group, compared with the LDCNSO-IEA+US group, LDCNSO-IEA and ultrasound were not used, and the rest were the same.

[0109] Fig. 9 The results show that the LDCNSO prepared in this example has no obvious cytotoxicity to L929 and VX2 cells. However, LDCNSO has no obvious cytotoxicity to L929 and VX2 cells under US (1W / cm 2, 50%, 5min) excitation showed obvious cytotoxicity, and the cell survival rate was only 20%, while the cell survival rate of the ultrasound group alone without LDCNSO was higher than 75%, indicating that LDCNSO can kill most VX2 liver cancer cells under the condition of ultrasonic excitation, indicating that LDCNSO can kill liver cancer cells under ultrasonic excitation and has great anti-liver cancer potential.

[0110] Fig.10 The effect of pH on the calcium ion release rate of the LDCNSO prepared in this example under different treatment conditions. The results show that when the pH is 6.0, LDCNSO can release Ca in a short burst within 10 minutes through ultrasonic stimulation. 2+ The release rate was as high as 80%. The release rate in the weakly alkaline environment of pH 7.4 was much lower than that in the weakly acidic microenvironment of the tumor site, indicating that LDCNSO can release a large amount of Ca by ultrasound triggering in the weakly acidic pH of the tumor microenvironment. 2+ .

[0111] Fig.11 The LDCNSO prepared in this example was used to detect intracellular Ca2+ in different treatment groups using Fluo-4 AM fluorescent probe. 2+ As shown in the figure, among the different groups, cells treated with LDCNSO+US showed the strongest fluorescence emission and fluorescence intensity. In sharp contrast, the control group and the group exposed to US only showed negligible fluorescence signals, confirming that LDCNSO can induce a large amount of Ca in tumor cells. 2+ release.

[0112] Fig.12 This is a bio-electron microscopy (Bio-TEM) image of VX2 cells treated with LDCNSO prepared in this example. As shown in the figure, the morphology of a few mitochondria in the US group and the LDCNSO group changed, and abnormal conditions such as rounding and swelling appeared; while most mitochondria in the LDCNSO+US group showed abnormal damage such as swelling, disappearance of cristae, and outflow of contents, which eventually led to the death of tumor cells.

[0113] Fig.13 The LDCNSO-IEA prepared in this example was tested in an in vivo rabbit orthotopic liver cancer model intervention experiment. The results showed that after 8 days of treatment, the tumor active foci in the LDCNSO-IEA+US group were significantly reduced or disappeared, while the tumor active foci in other treatment groups were still large or more active, which proved the reliability of this treatment plan and the effectiveness of the designed new embolic agent. In the H&E and TUNEL staining of tumor sections, compared with other treatment groups, the LDCNSO-IEA+US group showed that the best treatment effect was achieved, tumor cells were effectively killed, a large number of apoptosis and necrosis occurred, and tumor activity decreased.

[0114] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A method for preparing a persulfate-based interventional embolic agent, characterized in that: The following steps are involved: S1: Calcium oleate, oleic acid and ammonium persulfate are subjected to coordination reaction to obtain CNSO; S2: reacting lecithin, DSPE-PEG and CNSO in an organic solvent to obtain LDCNSO; S3: Mix iodized oil with LDCNSO to obtain a persulfate-based interventional embolic agent.

2. The method for preparing the persulfate-based interventional embolic agent according to claim 1, characterized in that: In step S1, the feed ratio of calcium oleate, oleic acid and ammonium persulfate is 40 mg: 1 mL: 20 mg.

3. The method for preparing the persulfate-based interventional embolic agent according to claim 1, characterized in that: In step S1, in the coordination reaction, the reaction solvent is a mixture of n-hexane and ethanol, and the mixing volume ratio is 10:3; the reaction temperature is room temperature, and the reaction time is 12 hours.

4. The method for preparing the persulfate-based interventional embolic agent according to claim 1, characterized in that: Step S2 includes: S2-1: Add lecithin and DSPE-PEG to chloroform to obtain a chloroform phospholipid solution; mix CNSO with n-hexane to obtain a CNSO suspension; S2-2: Mix the chloroform phospholipid solution and the CNSO suspension, and stir to react to obtain LDCNSO.

5. The method for preparing the persulfate-based interventional embolic agent according to claim 4, characterized in that: In step S2-1, the dosage ratio of lecithin, DSPE-PEG and chloroform is 1 mg:1 mg:1 mL; The feed ratio of CNSO to n-hexane is 25 mg:25 mL.

6. The method for preparing the persulfate-based interventional embolic agent according to claim 4, characterized in that: In step S2-2, in the chloroform phospholipid solution and the CNSO suspension, the feed ratio of CNSO to the chloroform phospholipid solution is 25 mg:5 mL.

7. The method for preparing the persulfate-based interventional embolic agent according to claim 4, characterized in that: In step S2-2, the reaction temperature is room temperature and the reaction time is 12 hours.

8. The method for preparing the persulfate-based interventional embolic agent according to claim 4, characterized in that: In step S3, the content of LDCNSO in the persulfate-based interventional embolic agent is 60 mg / kg.

9. A use of the persulfate-based interventional embolic agent according to any one of claims 1 to 8, characterized in that: The persulfate-based interventional embolic agent is used for preparing anti-tumor drugs.

10. A use of the persulfate-based interventional embolic agent according to any one of claims 1 to 8, characterized in that: The persulfate-based interventional embolic agent is used in the preparation of drugs loaded with persulfate or persulfate nanoparticles.